Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.
about
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disordersImproving accuracy of prognosis in patients with myelodysplastic syndromes using self-reported quality of life data. Opportunities for a new research agenda in developing prognostic models.Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes.Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.Prognostic factors in myelodysplastic syndromes.Patterns of blood product use among patients with myelodysplastic syndromeErythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes.Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.Synthetic and natural iron chelators: therapeutic potential and clinical useProphylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusion-dependent patients with myelodysplastic syndromes.Monthly blood transfusions decrease after four months of azacitidine.Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow.Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report.Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry.Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study.Value of transfusion independence in severe aplastic anemia from patients' perspectives - a discrete choice experiment
P2860
Q24186615-A7D5A99B-D43C-4F03-992A-E3DD14EBE3ECQ31054529-24939037-EC27-4DF1-820A-D7492E380EABQ33813750-9F324204-5F89-4B43-8DD8-4996775F66A0Q35824970-DD1E790E-2F32-4F35-A62E-2C72F2CB5ECCQ36446821-E2F9A092-7E95-4D84-9321-6E289B0F5912Q36671273-70A4B4DE-F58F-413C-8175-92D9B4C41538Q36846543-ADCE5AD3-AAD7-44D3-A442-9B7DB7E63C76Q36895801-4611ABB8-251B-4D4F-9DFE-A6C67B23D39AQ37125405-6C0DBC6F-4CA9-467A-ACAD-FED3BD94F584Q37290073-06A02D33-9591-481F-A656-40D8EB67471AQ40376149-C3BDE424-B42E-438F-8F5F-4F7D0188FF52Q41032522-77952B74-3F22-4CE6-816B-54EDD33E69EAQ42664574-C064D4F0-56EB-48F2-8CE2-45799E3F5CA6Q42672534-AEF46F25-5EB4-4E12-92E5-CE781330A7D9Q45340443-BAB0F12E-AB5A-4160-934C-8D9995E2699DQ48072592-FFB0B83F-BA46-4C49-8289-415E115B2FEAQ48175966-9DD07B3D-6F69-4E4B-B63B-B244DBB386E9Q50463311-B04F0AB2-D7DD-4E0F-986B-4975C90AE598Q56764372-D02B22CA-20FD-480C-A604-67A55AA95586
P2860
Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Transfusion independence in pa ...... outcomes and quality of life.
@ast
Transfusion independence in pa ...... outcomes and quality of life.
@en
type
label
Transfusion independence in pa ...... outcomes and quality of life.
@ast
Transfusion independence in pa ...... outcomes and quality of life.
@en
prefLabel
Transfusion independence in pa ...... outcomes and quality of life.
@ast
Transfusion independence in pa ...... outcomes and quality of life.
@en
P356
P1433
P1476
Transfusion independence in pa ...... outcomes and quality of life.
@en
P2093
Lodovico Balducci
P2860
P304
P356
10.1002/CNCR.21860
P407
P577
2006-05-01T00:00:00Z